Cue Health

Cue Health

Cue Health

Since 2016, we have been collaborating with Cue Health to accelerate the company’s vision to enable high-quality diagnostics, anywhere, anytime, exemplifying our commitment to advancing global public health and early intervention.

This long-standing collaboration, which first started with an investment by JJDC focused on combating HIV in the developing world, has now evolved to exploring the potential of the company’s test technology applied to areas like respiratory health, sexual health, cardiac and metabolic health, women’s health, men’s health, and chronic disease management.

As part of the Johnson & Johnson Family of Companies’ response to the COVID-19 pandemic, we expanded this collaboration to accelerate Cue’s COVID-19 molecular diagnostic test, which received two Emergency Use Authorizations from the U.S. Food and Drug Administration (FDA) for point-of-care and over-the-counter use.

At Cue, we are powering the digital transformation of healthcare by providing connected, lab-quality diagnostics anywhere. Johnson & Johnson Innovation first partnered with Cue in 2016 to help accelerate Cue's vision to provide high-quality diagnostics to the developing world, demonstrating their commitment to advancing healthcare technologies that benefit the whole world. Johnson & Johnson Innovation has backed Cue in funding rounds since the initial collaboration, helping to further accelerate Cue's evolution into a digital-first, healthcare technology company.

Ayub Khattak
Co-Founder and CEO, Cue Health